SEC Comment Letter for Seres Therapeutics, Inc. (MCRB) (CIK 0001609809) (MCRB) — Mar 13, 2020
Seres Therapeutics, Inc. (MCRB) (CIK 0001609809)
Date: March 13, 2020 · CIK: 0001609809 · Accession: 0000000000-20-002288
AI Filing Summary & Sentiment
File numbers found in text: 333-237033
Letter
March 13, 2020 Eric D. Shaff Chief Executive Officer Seres Therapeutics, Inc. 200 Sidney Street Cambridge, Massachusetts 02139 Re:Seres Therapeutics, Inc. Registration Statement on Form S-3 Filed March 9, 2020 File No. 333-237033 Dear Mr. Shaff: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Peter N. Handrinos, Esq.
Show Raw Text
March 13, 2020
Eric D. Shaff
Chief Executive Officer
Seres Therapeutics, Inc.
200 Sidney Street
Cambridge, Massachusetts 02139
Re:Seres Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 9, 2020
File No. 333-237033
Dear Mr. Shaff:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Peter N. Handrinos, Esq.